ESMO 2019 Congress

Oncology Meeting Resources

27 Sep - 01 Oct 2019, Barcelona, Spain

Translating science into better cancer patient care​

Presentations (slides) and webcasts are available to ESMO members according to the presenters' agreement to release them. Abstracts are open access. Congress attendees should access via the ESMO Conferences platform .
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

ESMO Videos:   Highlight series Expert Reports series

Special Sessions and Tracks

ESMO 2019 square

More Resources

Meeting programmeFuture ESMO meetings


Browse or search all resources from ESMO 2019 Congress





Format available

https://oncologypro.esmo.org/Meeting-Resour...ed-Unresectable-Hepatocellular-Carcinoma-HCC

BackgroundPts with unresectable HCC have few treatment (tx) options. Checkpoint inhibitors and combination approaches with anti-VEGFs are emerging as potential new tx options.

Date: 27 Sep 2019
Presenter: Michael Lee
Resources: Abstract, Presentation, Webcast
Topic: Hepatobiliary Cancers

https://oncologypro.esmo.org/Meeting-Resour...rectal-Invited-Discussant-LBA38_PR-and-LBA39

Date: 27 Sep 2019
Presenter: Arndt Vogel
Resources: Presentation, Webcast
Topic: Hepatobiliary Cancers

https://oncologypro.esmo.org/Meeting-Resour...f-a-multicenter-randomised-Phase-2-AIO-trial

BackgroundThe optimal preoperative treatment for LAPC is unknown. This first prospective, randomised trial was designed to compare the efficacy and safety of nab-Paclitaxel and Gemcitabine (nPG) with...

Date: 27 Sep 2019
Presenter: Volker Kunzmann
Resources: Abstract, Presentation, Webcast
Topic: Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...dvanced-or-metastatic-cholangiocarcinoma-CCA

BackgroundFibroblast growth factor receptor (FGFR) 2 alterations are implicated in CCA. Pemigatinib is a selective, potent, oral FGFR1, 2, and 3 inhibitor. We present data from a phase II, open label,...

Date: 27 Sep 2019
Presenter: Arndt Vogel
Resources: Abstract, Presentation, Webcast
Topic: Hepatobiliary Cancers

https://oncologypro.esmo.org/Meeting-Resour...colorectal-Invited-Discussant-671O-and-LBA40

Date: 27 Sep 2019
Presenter: Per Pfeiffer
Resources: Presentation, Webcast
Topic: Gastrointestinal Cancers

https://oncologypro.esmo.org/Meeting-Resour...dated-Results-From-the-Phase-3-SPARTAN-Study

BackgroundIn the phase 3 placebo (PBO)-controlled SPARTAN study, APA with ongoing androgen deprivation therapy (ADT) significantly improved metastasis-free survival (MFS) (HR, 0.28; 95% CI, 0.23-0.

Date: 27 Sep 2019
Presenter: Matthew Smith
Resources: Abstract, Presentation, Webcast
Topics: Prostate Cancer, Genitourinary Cancers

https://oncologypro.esmo.org/Meeting-Resour...-and-sub-group-analysis-by-metastatic-burden

BackgroundSTAMPEDE has previously reported that upfront docetaxel (Doc) improved overall survival (OS) for patients (pts) starting long-term androgen deprivation therapy (ADT).

Date: 27 Sep 2019
Presenter: Nicholas James
Resources: Abstract, Presentation, Webcast
Topic: Prostate Cancer

https://oncologypro.esmo.org/Meeting-Resour...rs-prostate-Invited-Discussant-843O-and-844O

Date: 27 Sep 2019
Presenter: Karim Fizazi
Resources: Presentation, Webcast
Topic: Prostate Cancer

https://oncologypro.esmo.org/Meeting-Resour...-Randomised-Controlled-Trial-RCT-NCT00541047

BackgroundThe optimal timing of RT after RP for prostate cancer (PCa) is uncertain. RADICALS-RT compared the efficacy and safety of adjuvant RT (aRT) versus an observation policy with salvage RT for PSA failure (Obs+sRT).

Date: 27 Sep 2019
Presenter: Chris Parker
Resources: Abstract, Presentation, Webcast
Topics: Prostate Cancer, Radiation Oncology, Genitourinary Cancers, Therapy

https://oncologypro.esmo.org/Meeting-Resour...ctively-planned-aggregate-data-meta-analysis

BackgroundThree randomised trials, RADICALS (ISRCTN40814031), GETUG-AFU 17 (NCT00667069) and RAVES (NCT00860652), have compared adjuvant radiotherapy (ART) with a policy of salvage radiotherapy for PSA...

Date: 27 Sep 2019
Presenter: Claire Vale
Resources: Abstract, Presentation, Webcast
Topic: Prostate Cancer